Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib rollover long-term safety extension study
NL-OMON48832Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenvatinib in thyroid cancer and renal cell carcinoma (RCC) (3 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Long-term safety. Started Sep 2018; status: completed.
02
Drugs
lenvatinib
03
Conditions
thyroid cancerrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON48832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48832.